Table 2.
Univariate and multivariate analysis of time-to-progression and overall survival in melanoma, modified melanoma, and NSCLC cohorts
| Time-to-progression | Overall survival | |||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Melanoma cohort | ||||||||
| Treatment (ICI+COXi vs ICI alone) | 0.48 (0.29 to 0.77) | 0.003 | 0.36 (0.2 to 0.66) | <0.001 | 0.97 (0.56 to 1.67) | 0.91 | – | – |
| Age (per year) | 0.99 (0.97 to 1.01) | 0.441 | 0.99 (0.96 to 1.02) | 0.44 | 1.01 (0.99 to 1.03) | 0.804 | – | – |
| Pretreatment NLR (high (>5) vs low (≤5)) | 1.76 (1.08 to 2.87) | 0.024 | 3.21 (1.64 to 6.3) | <0.001 | 2.44 (1.38 to 4.33) | 0.002 | – | – |
| Pretreatment NLR (per unit log-scale) | 1.45 (1.07 to 1.96) | 0.016 | 2.11 (1.3 to 3.41) | 0.002 | – | – | – | – |
| Female gender | 0.62 (0.38 to 1.02) | 0.062 | 0.34 (0.18 to 0.66) | 0.001 | 0.77 (0.44 to 1.35) | 0.357 | – | – |
| Steroid use (yes vs no) | 0.66 (0.42 to 1.05) | 0.08 | – | – | 0.81 (0.48 to 1.37) | 0.423 | – | – |
| Modified melanoma cohort | ||||||||
| Treatment (ICI+COXi vs ICI alone) | 0.51 (0.29 to 0.9) | 0.017 | 0.31 (0.15 to 0.64) | 0.002 | 0.95 (0.5 to 1.79) | 0.865 | – | – |
| Age (per year) | 1 (0.98 to 1.02) | 0.683 | 0.98 (0.95 to 1.02) | 0.307 | 1.01 (0.98 to 1.04) | 0.552 | – | – |
| Pretreatment NLR (high (>5) vs low (≤5)) | 1.93 (1.14 to 3.44) | 0.015 | 3.33 (1.56 to 7.13) | 0.002 | 2.47 (1.28 to 4.75) | 0.007 | – | – |
| Pretreatment NLR (per unit log-scale) | 1.51 (1.08 to 2.09) | 0.015 | 2.43 (1.37 to 4.33) | 0.003 | – | – | – | – |
| Female gender | 0.54 (0.3 to 0.98) | 0.043 | 0.17 (0.07 to 0.43) | <0.001 | 0.79 (0.4 to 1.53) | 0.477 | – | – |
| Steroid use (yes vs no) | 0.65 (0.38 to 1.12) | 0.122 | – | – | 0.74 (0.4 to 1.38) | 0.347 | – | – |
| NSCLC cohort | ||||||||
| Treatment (ICI+COXi vs ICI alone) | 0.48 (0.23 to 1.03) | 0.059 | 0.45 (0.21 to 0.97)* | 0.042 | 0.32 (0.13 to 0.8) | 0.015 | 0.3 (0.12 to 0.78)* | 0.013 |
| 0.52 (0.24 to 1.14)† | 0.101 | 0.4 (0.15 to 1.04)† | 0.06 | |||||
| Age (per year) | 0.96 (0.92 to 1.01) | 0.086 | 0.96 (0.91 to 1.02)* | 0.062 | 1 (0.95 to 1.05) | 0.863 | 0.99 (0.94 to 1.04)* | 0.574 |
| Pretreatment NLR (high (>5) vs low (≤5)) | 1.39 (0.65 to 2.99) | 0.394 | 1.23 (0.57 to 2.69)† | 0.597 | 3.69 (1.35 to 10.05) | 0.011 | 3.06 (1.1 to 8.51)† | 0.033 |
| Steroid use (yes vs no) | 0.85 (0.4 to 1.79) | 0.662 | – | – | – | – | ||
*Multivariate model with treatment received and age.
†Multivariate model with treatment received and pretreatment NLR.
COXi, cyclo-oxygenase inhibitors; ICI, immune checkpoint inhibitor; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer.